Jony Sheynin1,2, Elizabeth R Duval1,2, Anthony P King1,2, Mike Angstadt2, K Luan Phan3, Naomi M Simon4,5, Sheila A M Rauch6,7, Israel Liberzon1,2. 1. Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. 2. Department of Psychiatry, University of Michigan, Ann Arbor, Michigan. 3. Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio. 4. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Psychiatry, New York University Medical School, New York, New York. 6. Mental Health Service Line, Atlanta VA Healthcare System, Decatur, Georgia. 7. Department of Psychiatry and Behavioral Sciences, School of Medicine, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Alterations in resting-state functional connectivity (rsFC) have been reported in posttraumatic stress disorder (PTSD). Here, we examined pre- and post-treatment rsFC during a randomized clinical trial to characterize alterations and examine predictors of treatment response. METHODS: Sixty-four combat veterans with PTSD were randomly assigned to prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline. Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans occurred before and after treatment. Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake. Seed-based and region of interest (ROI)-to-ROI connectivities, as well as an exploratory connectome-based approach were used to analyze rsFC patterns. Based on previously reported findings, analyses focused on Salience Network (SN) and Default-Mode Network (DMN). RESULTS: At intake, patients with PTSD showed greater DMN-dorsal attention network (DAN) connectivity (between ventromedial prefrontal cortex and superior parietal lobule; family-wise error corrected p = .011), greater SN-DAN connectivity (between insula and middle frontal gyrus; corrected p = .003), and a negative correlation between re-experiencing symptoms and within-DMN connectivity (between posterior cingulate cortex (PCC) and middle temporal gyrus; corrected p < .001). We also found preliminary evidence for associations between rsFC and treatment response. Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). CONCLUSIONS: Our findings suggest neural abnormalities in PTSD and may inform future research examining neural biomarkers of PTSD treatment response. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Alterations in resting-state functional connectivity (rsFC) have been reported in posttraumatic stress disorder (PTSD). Here, we examined pre- and post-treatment rsFC during a randomized clinical trial to characterize alterations and examine predictors of treatment response. METHODS: Sixty-four combat veterans with PTSD were randomly assigned to prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline. Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans occurred before and after treatment. Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake. Seed-based and region of interest (ROI)-to-ROI connectivities, as well as an exploratory connectome-based approach were used to analyze rsFC patterns. Based on previously reported findings, analyses focused on Salience Network (SN) and Default-Mode Network (DMN). RESULTS: At intake, patients with PTSD showed greater DMN-dorsal attention network (DAN) connectivity (between ventromedial prefrontal cortex and superior parietal lobule; family-wise error corrected p = .011), greater SN-DAN connectivity (between insula and middle frontal gyrus; corrected p = .003), and a negative correlation between re-experiencing symptoms and within-DMN connectivity (between posterior cingulate cortex (PCC) and middle temporal gyrus; corrected p < .001). We also found preliminary evidence for associations between rsFC and treatment response. Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). CONCLUSIONS: Our findings suggest neural abnormalities in PTSD and may inform future research examining neural biomarkers of PTSD treatment response. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Sheila A M Rauch; H Myra Kim; Corey Powell; Peter W Tuerk; Naomi M Simon; Ron Acierno; Carolyn B Allard; Sonya B Norman; Margaret R Venners; Barbara O Rothbaum; Murray B Stein; Katherine Porter; Brian Martis; Anthony P King; Israel Liberzon; K Luan Phan; Charles W Hoge Journal: JAMA Psychiatry Date: 2019-02-01 Impact factor: 21.596
Authors: William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2008-12-24 Impact factor: 5.067
Authors: Xi Zhu; Benjamin Suarez-Jimenez; Amit Lazarov; Liat Helpman; Santiago Papini; Ari Lowell; Ariel Durosky; Martin A Lindquist; John C Markowitz; Franklin Schneier; Tor D Wager; Yuval Neria Journal: Depress Anxiety Date: 2018-09-10 Impact factor: 6.505
Authors: Elizabeth R Duval; Jony Sheynin; Anthony P King; K Luan Phan; Naomi M Simon; Brian Martis; Katherine E Porter; Sonya B Norman; Israel Liberzon; Sheila A M Rauch Journal: Depress Anxiety Date: 2020-04-19 Impact factor: 8.128
Authors: Chadi G Abdallah; Christopher L Averill; Amy E Ramage; Lynnette A Averill; Selin Goktas; Samaneh Nemati; John H Krystal; John D Roache; Patricia A Resick; Stacey Young-McCaughan; Alan L Peterson; Peter Fox Journal: Chronic Stress (Thousand Oaks) Date: 2019-05-15
Authors: Andrew A Nicholson; Daniela Rabellino; Maria Densmore; Paul A Frewen; David Steryl; Frank Scharnowski; Jean Théberge; Richard W J Neufeld; Christian Schmahl; Rakesh Jetly; Ruth A Lanius Journal: Brain Behav Date: 2021-12-18 Impact factor: 2.708
Authors: Alyssa R Roeckner; Katelyn I Oliver; Lauren A M Lebois; Sanne J H van Rooij; Jennifer S Stevens Journal: Transl Psychiatry Date: 2021-10-05 Impact factor: 6.222
Authors: Paul Zhutovsky; Jasper B Zantvoord; Judith B M Ensink; Rosanne Op den Kelder; Ramon J L Lindauer; Guido A van Wingen Journal: Neuroimage Clin Date: 2021-11-26 Impact factor: 4.881